Daniel Liebler
Faculty Member
Last active: 2/15/2016

Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.

Ellis MJ, Gillette M, Carr SA, Paulovich AG, Smith RD, Rodland KK, Townsend RR, Kinsinger C, Mesri M, Rodriguez H, Liebler DC, Clinical Proteomic Tumor Analysis Consortium (CPTAC)
Cancer Discov. 2013 3 (10): 1108-12

PMID: 24124232 · PMCID: PMC3800055 · DOI:10.1158/2159-8290.CD-13-0219

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods.

©2013 AACR.

MeSH Terms (19)

Biomarkers, Tumor Breast Neoplasms Colonic Neoplasms Computational Biology Female Genome, Human Genomics Genomics Genotype Humans Molecular Sequence Annotation Mutation National Cancer Institute (U.S.) National Human Genome Research Institute (U.S.) Neoplasms Ovarian Neoplasms Phenotype Proteomics United States

Connections (1)

This publication is referenced by other Labnodes entities: